STK11/LKB1 genetic alterations are associated with shorter progression-free and overall survival with PD-1 blockade among KRAS-mutant LUAC in the SU2C.

Slides:

Advertisements

Similar presentations

Experience and Outcomes with Hypofractionated Concurrent Chemoradiation for Stage III NSCLC at NCCC Gregory Webb Medical Student.

Advertisements

What are the main benefits of BRAF inhibitors in metastatic melanoma?

Date of download: 5/29/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Adjuvant Chemotherapy With Gemcitabine and Long-term.

Presented By Alan Venook at 2016 ASCO Annual Meeting

Date of download: 9/18/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Genetic and Histological Assessment of Surgical Margins.

Dose-escalation patient response.

A Paradigm Shift From One-Size-Fits-All to Tailor-Made Therapy for Metastatic Colorectal Cancer.

Summary of genetic alterations in resistant biopsies among patients progressing on ceritinib or alectinib. Summary of genetic alterations in resistant.

Figure 4 Cerebrospinal fluid levels of neurofilament light chain

WT G>A G>C G>T (n = 93) (n = 21) (n = 10) (n = 51)

NSCLC. NSCLC. A, antitumor activity of abemaciclib in 4 KRAS-mutant (NCI-H358, NCI-H2122, NCI-H441, NCI-H460) and 2 KRAS wild-type (WT; NCI-H1650, NCI-H1975)

Frequency of JAK1 and JAK2 alterations and their association with overall survival in TCGA datasets. Frequency of JAK1 and JAK2 alterations and their association.

Prognostic significance of DDB2 in ovarian cancer.

Surviving the First Year of Peritoneal Dialysis: Enduring Hard Times

Emergence of resistance to immune checkpoint blockade is associated with elimination of mutation-associated neoantigens by LOH and a more diverse T-cell.

Kaplan–Meier curves for a, b) progression-free survival (PFS) and c, d) overall survival (OS) in a, c) large-cell neuroendocrine carcinoma patients and.

A–d) Comparison of Kaplan–Meier curves of a) progression-free survival (PFS) and c) overall survival (OS) in large-cell neuroendocrine carcinoma (LCNEC)

Volume 20, Issue 1, Pages (January 2012)

Treatment of human MCC tumors with intralesional IFNβ is associated with MHC-I upregulation. Treatment of human MCC tumors with intralesional IFNβ is associated.

Kaplan–Meier survival curves of overall survival (OS) for EGFR mutant lung adenocarcinoma patients who received epidermal growth factor receptor tyrosine.

Statistical Considerations in Studies of Late Effects in HCT

(A) Survival time. (A) Survival time. All patients. (a) PFS since the start of EGFR-TKI (groups A, B and C). (b) OS since the start of EGFR-TKI (groups.

PFS by dose of nivolumab for (A) all patients (n=47), (B) PD-L1-positive patients (n=13) and (C) PD-L1-negative or unknown patients (n=34). mPFS, median.

Kaplan-Meier curves of OS by dose of nivolumab for (A) all patients (n=47), (B) PD-L1-positive patients (n=13) and (C) PD-L1-negative or unknown patients.

Kaplan-Meier-estimated PFS and OS are presented, with PFS in c-Met high and low patients shown in (A), OS in c-Met high and low patients in (B), PFS in.

Kaplan–Meier curves of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) progression-free survival (PFS) for EGFR mutant lung adenocarcinoma.

Computed tomographic images from a patient with BRAFL597S-mutant metastatic melanoma responding to therapy with the MEK inhibitor TAK-733. Computed tomographic.

Fig. 2. Clinically actionable somatic genomic alterations in various tumor types. Clinically actionable somatic genomic alterations in various tumor types.

Comparison of survival in patients with BAV (A) and TAV (B) in the US cohort using Kaplan-Meier curves, stratified by whether or not they had suffered.

Distinct molecular and clinical correlates of H3F3A mutation subgroups

(A) Progression-free survival in patients with BRCA-mutated HER2-negative breast cancer treated with PARPi versus those treated with monochemotherapy (controls).

Unadjusted event-free survival (days alive and out-of-hospital) of participants with and without MCI in (A) overall cohort, (B) standard management cohort.

Association between RB pathway alterations and poor prognosis in early-stage lung adenocarcinoma patients. Association between RB pathway alterations and.

CXCL14-positive CAFs induce overexpression of LINC00092 in ovarian cancer. CXCL14-positive CAFs induce overexpression of LINC00092 in ovarian cancer. A,

Immune signatures of patients with short-, medium-, and long-term survival. Immune signatures of patients with short-, medium-, and long-term survival.

Efficacy of nivolumab in Japanese patients with advanced non-squamous non-small cell lung cancer (A) Kaplan-Meier curve for PFS, (B) Kaplan-Meier curve.

Antitumor activity of AMG 102 in combination with bevacizumab or motesanib. Antitumor activity of AMG 102 in combination with bevacizumab or motesanib.

Somatic mutational rates and survival analysis of IBD-CRC.

ALDH1A3 expression levels are inversely correlated with the survival of patients with resectable mass-forming and advanced cholangiocarcinoma, respectively.

Kaplan–Meier curves for PFS and OS (for patients treated with anti-PD-1/PD-L1 monotherapy). Kaplan–Meier curves for PFS and OS (for patients treated with.

Nomogram depicting estimates of postprogression survival, including estimates of 6-, 12-, and 24-month OS according to prechemotherapy and postchemotherapy.

Progression-free (a) and overall (b) survival by age subgroup, Kaplan-Meier plots. Progression-free (a) and overall (b) survival by age subgroup, Kaplan-Meier.

A protracted ketogenic diet increases radiation response in H292 lung cancer xenografts given conventional fractionated radiation. A protracted ketogenic.

Survival risk prediction analysis and application of the metastasis gene signature. Survival risk prediction analysis and application of the metastasis.

Kaplan-Meier survival analysis of p53 mutation in the overall breast tumor series. Kaplan-Meier survival analysis of p53 mutation in the overall breast.

MYC–HOXB7–HER2 predicts clinical outcome in breast cancer patients treated with tamoxifen. MYC–HOXB7–HER2 predicts clinical outcome in breast cancer patients.

Influence of ASGR2 expression on survival.

Location of the ER mutations and frequencies per cohort.

Kaplan–Meier analysis of PFS and OS in patients with advanced non-small cell lung cancer with adenocarcinoma histology with time since start of first-line.

Stk11/Lkb1 ablation directly promotes primary resistance to PD-L1/PD-1 blockade in immunocompetent murine models of Kras-mutant LUAC. Stk11/Lkb1-proficient/deficient.

Increased frequency and number of KLL-specific clonotypes in tumors is associated with improved MCC-specific survival. Increased frequency and number of.

Genomic determinants of response to cytotoxic chemotherapy.

Genetic analysis suggests the presence of four clinically relevant groups of histologically defined anaplastic oligodendrogliomas. Genetic analysis suggests.

Patient stratification using survival risk prediction and BCLC staging

Progression and survival analysis.

Blocking αvβ3/galectin-3 binding with GCS-100 selectively kills KRAS-addicted lung cancer cells. Blocking αvβ3/galectin-3 binding with GCS-100 selectively.

KRAS-mutant lung adenocarcinoma subsets exhibit distinct patterns of immune system engagement. KRAS-mutant lung adenocarcinoma subsets exhibit distinct.

Expression of TGFβ ligands in GBM

TMEscore is a prognostic biomarker and predicts immunotherapeutic benefit. TMEscore is a prognostic biomarker and predicts immunotherapeutic benefit. A,

STK11/LKB1 comutations are associated with inferior objective response rate with PD-1 blockade in KRAS-mutant LUAC. A, Objective response rate (RECISTv1.1)

STK11/LKB1 mutations are a genomic determinant of poor clinical outcome with PD-1 axis blockade in PD-L1–positive nonsquamous NSCLC, regardless of KRAS.

Cell counts of immune infiltrate and expression of galectin-1 and galectin-3 in the short-, medium-, and long-term survival cohorts. Cell counts of immune.

Kaplan-Meier estimates for survival in metastatic disease for the whole patient cohort (A) and in patients with or without history of adjuvant trastuzumab.

ARQ 531 improves survival in the Eμ-TCL1 engraftment model compared with ibrutinib. ARQ 531 improves survival in the Eμ-TCL1 engraftment model compared.

BIM expression predicts the response of patients with EGFR-mutant lung cancers. BIM expression predicts the response of patients with EGFR-mutant lung.

KRAS co-mutations are associated with distinct therapeutic vulnerabilities. KRAS co-mutations are associated with distinct therapeutic vulnerabilities.

DYNLRB1, AIMP1, and NPIPA1 expression correlate with survival in neuroblastoma. DYNLRB1, AIMP1, and NPIPA1 expression correlate with survival in neuroblastoma.

Coincidence and prognostic significance of PD-1+ and CD103+ cells in HGSC. Serial sections from the 490-case TMA were stained with antibodies to CD103.

MITF-low/NF-κB–high transcriptional class is present and associated with resistance to MAPK pathway inhibition in human tumors. MITF-low/NF-κB–high transcriptional.

Kaplan–Meier curves of relapse-free survival of the CAR-T cohort (left) and the HCT cohort (right) of 8 CAR-T patients and 12 HCT patients whose preceding.

Presentation transcript:

STK11/LKB1 genetic alterations are associated with shorter progression-free and overall survival with PD-1 blockade among KRAS-mutant LUAC in the SU2C cohort. STK11/LKB1 genetic alterations are associated with shorter progression-free and overall survival with PD-1 blockade among KRAS-mutant LUAC in the SU2C cohort. A, Kaplan–Meier estimates of progression-free survival with PD-1 blockade in the KL, KP, K-only subgroups (left) and in the two-group comparison between KRASMUT;STK11/LKB1MUT (KL) and KRASMUT;STK11/LKB1WT LUAC (encompassing KP and K-only tumors; right). Tick marks represent data censored at the last time the patient was known to be alive and without disease progression (date of last radiologic assessment). mPFS, median progression-free survival. B, Kaplan–Meier estimates of overall survival with PD-1 inhibitors in the KL, KP, K-only subgroups (left) and in the two-group comparison between KRASMUT;STK11MUT (KL) and KRASMUT;STK11/LKB1WT tumors (right). Tick marks represent data censored at the last time the patient was known to be alive. mOS, median overall survival. Ferdinandos Skoulidis et al. Cancer Discov 2018;8:822-835 ©2018 by American Association for Cancer Research